TRILUMINATE Pivotal Study for Abbott’s TriClip device

Posted on Updated on

According to Professor Georg Nickenig, lead investigator of the study and chair of Internal Medicine and Polyclinic II at the University of Bonn, Germany, presented findings. Data show a TR reduction of at least one grade in 87 percent of patients with symptomatic or greater TR and improvements in quality-of-life, “The TriClip is a version of the MitraClip used for transcatheter mitral valve repair (TMVR) to resolve mitral regurgitation. A post hoc registry analysis of MitraClip use for TR has indicated TR reduction and improved clinical outcomes out to one year. Treatment for TR is currently limited to the use of diuretics and high-risk surgical procedures. Nickenig said minimally invasive catheter-based procedures (such as TriClip) may reduce TR with low procedural risk.”

 

TriClip Device For Tricuspid Regurgitation Effective at One Year in TRILUMINATE Study

Advertisements

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.